No Data
No Data
WUXI XDC: Interim Report 2024
WuXi XDC Cayman Inc.'s (HKG:2268) Largest Shareholders Are Private Companies With 50% Ownership, Public Companies Own 33%
[Brokerage Focus] Guosen Securities maintains its "outperform" rating on CStone Pharmaceuticals (02268) due to its rapid expansion of production capacity and significant improvement in profitability.
Jingu Financial | Guosen Securities issued a research report, stating that CStone Pharmaceuticals (02268) achieved a total revenue of 1.665 billion yuan (+67.6%) and a net income of 0.488 billion yuan (+175.5%) in the first half of 2024. The adjusted net income under Non-IFRS was 0.534 billion yuan (+146.6%). The company's gross margin for the first half of 2024 was 32.15% (+9.1pp), and the net margin was 28.72% (+11.5pp), demonstrating a significant improvement in profitability. The bank pointed out that the company had a total of 705 ongoing projects in the first half of 2024, compared to 20...
HK Stocks | WuXi Biologics (02268) rises by over 4% again as global ADC demand continues to rise, with the company's first half revenue increasing by 68% year-on-year.
Pharmacyclics (02268) rose more than 4%, as of the time of drafting, up 4.12%, at HKD 20.7, with a trading volume of HKD 44.5142 million.
WuXi XDC Announces Strong Growth and Revised Caps
Citi: Maintains a "buy" rating on WuXi AppTec (02268), with a target price raised to HK$43.
Citi expects strong project momentum to continue supporting the growth of WuXi Biologics (02268), with revenue expected to increase by 60% and 42% year-on-year in the next two years.
No Data
No Data
SoundOfMusic : The partial list shown looks to be ranked.
if so, Xpeng is ranked #10 out of 50 in the Fortune Top 50 Tech in China. It doesn't surprise me.